Darren Pan
Overview
Explore the profile of Darren Pan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Avigan Z, Arinsburg S, Pan D, Mark T, Fausel C, Bubalo J, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):115.
PMID: 39424960
No abstract available.
2.
Avigan Z, Bodnar S, Pan D, Catlett J, Richter J, Sanchez L, et al.
Blood Adv
. 2024 Oct;
9(1):202-206.
PMID: 39383457
No abstract available.
3.
Pan D, Richter J
Curr Hematol Malig Rep
. 2024 Aug;
19(6):237-245.
PMID: 39145912
Purpose Of Review: The introduction of bispecific antibodies is one of the most significant recent advances in the treatment of relapsed/refractory multiple myeloma. This review will summarize the management of...
4.
Avigan Z, Arinsburg S, Pan D, Mark T, Fausel C, Bubalo J, et al.
Bone Marrow Transplant
. 2024 Jul;
59(10):1440-1448.
PMID: 39085373
Autologous stem cell transplantation is a standard treatment strategy for patients with multiple myeloma that requires effective mobilization and apheresis of peripheral blood progenitor cells; however, in the current era...
5.
Saldarriaga M, Pan D, Unkenholz C, Mouhieddine T, Velez-Hernandez J, Engles K, et al.
Blood Adv
. 2024 May;
8(15):3859-3869.
PMID: 38776397
B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T cells (CAR-Ts) used in multiple myeloma (MM) are rapidly becoming a mainstay in the treatment of relapsed/refractory (R/R) disease, and CAR-T expansion...
6.
Richter J, Pan D, Salinardi T, Rice M
EJHaem
. 2023 Nov;
4(4):984-994.
PMID: 38024614
Stem cell transplantation (SCT) has been an integral treatment modality for multiple myeloma (MM) for decades. However, as standard-of-care therapies have improved, the benefit of SCT has been repeatedly called...
7.
Pan D, Richter J
Cancer Manag Res
. 2023 Jul;
15:741-751.
PMID: 37497430
Teclistamab is a BCMAxCD3 bispecific antibody, the first approved for the treatment of relapsed or refractory multiple myeloma. Given its impressive efficacy in heavily pretreated patients and better accessibility compared...
8.
Pan D, Mouhieddine T, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, et al.
Semin Oncol
. 2023 Apr;
50(1-2):40-48.
PMID: 37005144
Panobinostat is an oral pan histone-deacetylase inhibitor used in the treatment of relapsed and refractory multiple myeloma. Previously published studies of panobinostat demonstrated synergy with bortezomib but included few patients...
9.
Mouhieddine T, Van Oekelen O, Melnekoff D, Li J, Ghodke-Puranik Y, Lancman G, et al.
Blood Adv
. 2022 Aug;
7(6):1056-1064.
PMID: 36018226
T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and bispecific antibodies (BiAbs) has shown promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), leading to the...
10.
Pan D, Richter J
Front Oncol
. 2022 Feb;
11:819127.
PMID: 35127532
Multiple myeloma remains an incurable disease despite numerous novel agents being approved in the last decade. Furthermore, disease behavior and susceptibility to current treatments often vary drastically from patient to...